We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




High Leptin Levels Increase Breast Cancer Risk

By Biotechdaily staff writers
Posted on 09 Dec 2002
Researchers have found that leptin, an adipocyte-derived cytokine associated with weight gain, promotes breast cancer cell growth, which may help to explain the association between weight gain and increased breast cancer risk. More...
Their finding was reported in the November 20, 2002, issue of the Journal of the National Cancer Institute.

To investigate whether leptin was associated with breast cancer, investigators from the University of Minnesota (Austin, USA; www.umn.edu) and colleagues determined the expression of leptin's receptor OB-Rb in human breast epithelial HBL100 cells and human breast carcinoma-derived T-47D cells, determined whether leptin influenced the proliferation of these cells, and evaluated the structure of mammary tissue in genetically obese leptin-deficient and leptin receptor-deficient mice.

Results showed that, in the presence of leptin, the number of cancerous breast cells increased 150% as compared to 50% for normal breast cells. In an experiment designed to assess the cells' ability to form tumors, it was found that only the breast cancer cell line exposed to leptin responded and proliferated. Obese leptin-deficient and leptin receptor-deficient mice had minimal epithelial development in the mature mammary gland compared with their lean counterparts.

"These findings may explain why weight gain, which is accompanied by higher-than expected leptin concentrations, also has been associated with increased breast cancer risk,” explained senior author Dr. Margot P. Cleary of the University of Minnesota's Hormel Institute. "Preventive measures need to be taken to control these deadly diseases.”



Related Links:
University of Minnesota

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Portable POCT Blood Gas Analyzer
BD100
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.